Bicalutamide is an antiandrogen medication for prostate cancer, marketed by AstraZeneca PLC as Casodex with 29 DMF and 12 MF approved before 2021 Q3.

Prochem implemented process validation with batch size above 100 KG in 2019, and can provide finished product as white powder with above 99.90% purity.

Product Name: Bicalutamide

CAS Number: 90357-06-5

Indication: Prostate cancer

Specification: USP 42

Certificate: PIC/S GMP certificate of bay factory / DMF from TFDA

Non-infringement Description:

• US4636505A is original substance patent of Bicalutamide, and already expired on 2008.10.01.
• JPS5933250A is family patent of US4636505A in Japan, and already expired on 2009.05.28.
• No related patent submitted in Taiwan.
• In this situation, no infringement concerns arise.